Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YWAHM
ADC Name
DS-6000
Synonyms
DS 6000; DS-6000; DS-6000a; DS6000; Raludotatug deruxtecan
   Click to Show/Hide
Organization
Daiichi Sankyo Co., Ltd.
Drug Status
Phase 2/3
Indication
In total 6 Indication(s)
Fallopian tube cancer
Phase 3
Clinical Trial
Ovarian cancer
Phase 3
Clinical Trial
Peritoneal cancer
Phase 3
Clinical Trial
Lung cancer
Phase 2
Clinical Trial
Solid tumor
Phase 2
Clinical Trial
Kidney cancer
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
8
Structure
Antibody Name
Raludotatug
  Antibody Info 
Antigen Name
Cadherin-6 (CDH6)
  Antigen Info 
Payload Name
DX-8951 derivative (DXd)
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Linker Name
Mc-Gly-Gly-Phe-Gly
  Linker Info 
Conjugate Type
Random Cysteines
Combination Type
deruxtecan
Puchem SID
355207085
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Objective Response Rate (ORR)  NCT04707248
Phase 1
Phase 1, two-part, multi-center, first-in-human study of DS-6000A in subjects with advanced renal cell carcinoma and ovarian tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Objective Response Rate (ORR)
13.30% (all)
Patients Enrolled
Patients with advanced renal cell carcinoma or ovarian cancer. Patients had received a median of 4 prior systemic therapy.
Administration Dosage
First dose was 1.60 mg/kg followed by 3.20, 4.80, 6.40, 8.00, and 9.60 mg/kg every 3 weeks.
Related Clinical Trial
NCT Number NCT04707248  Clinical Status Phase 1
Clinical Description Phase 1, two-part, multi-center, first-in-human study of DS-6000A in subjects with advanced renal cell carcinoma and ovarian tumors.
References
Ref 1 Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC). J Clin Oncol. 2022 40:16_suppl, 3002-3002.